Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
Climb Bio (Nasdaq: CLYM) has announced that it will present data at the American Society of Nephrology Kidney Week 2024, taking place in San Diego, CA from October 23-27, 2024. The presentation will feature a poster titled 'A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy'.
The presenter will be Dr. Frank Cortazar, Director of the New York Nephrology Vasculitis and Glomerular Center, Chief of the Division of Nephrology at St. Peter's Hospital, Chief of Clinical Research at St. Peter's Health Partners, and Clinical Scientist at Massachusetts General Hospital. The poster session, focusing on Membranous Nephropathy, FSGS, and Minimal Change Disease, is scheduled for October 24, 2024, from 10:00 a.m. to 12:00 p.m. PT, with the poster board number TH-PO587.
Climb Bio (Nasdaq: CLYM) ha annunciato che presenterà dati durante la American Society of Nephrology Kidney Week 2024, che si svolgerà a San Diego, CA, dal 23 al 27 ottobre 2024. La presentazione includerà un poster intitolato 'Uno studio open-label di fase 1b con un braccio singolo su Budoprutug, un anticorpo monoclonale anti-CD19 con ADCC potenziato, nella nefropatia membranosa primaria'.
Il presentatore sarà il Dr. Frank Cortazar, Direttore del New York Nephrology Vasculitis and Glomerular Center, Capo della Divisione di Nefrologia presso l'Ospedale di St. Peter, Capo della Ricerca Clinica presso St. Peter's Health Partners e Scienziato Clinico presso il Massachusetts General Hospital. La sessione del poster, incentrata sulla nefropatia membranosa, FSGS e malattia a cambiamenti minimi, è programmata per il 24 ottobre 2024, dalle 10:00 alle 12:00 ora del Pacifico, con il numero di poster TH-PO587.
Climb Bio (Nasdaq: CLYM) ha anunciado que presentará datos en la American Society of Nephrology Kidney Week 2024, que se llevará a cabo en San Diego, CA, del 23 al 27 de octubre de 2024. La presentación contará con un cartel titulado 'Un estudio abierto de fase 1b con un solo brazo de Budoprutug, un anticuerpo monoclonal anti-CD19 con ADCC mejorado en la nefropatía membranosa primaria'.
El presentador será el Dr. Frank Cortazar, Director del Centro de Vasculitis y Glomerulopatías de Nefrología de Nueva York, Jefe de la División de Nefrología en el Hospital de St. Peter, Jefe de Investigación Clínica en St. Peter's Health Partners y Científico Clínico en el Massachusetts General Hospital. La sesión de carteles, que se centra en la nefropatía membranosa, FSGS y la enfermedad de cambios mínimos, está programada para el 24 de octubre de 2024, de 10:00 a.m. a 12:00 p.m. PT, con el número de cartel TH-PO587.
클라임 바이오(나스닥: CLYM)는 2024년 10월 23일부터 27일까지 캘리포니아주 샌디에고에서 열리는 미국 신장학회 신장 주간 2024에서 데이터를 발표할 것이라고 발표했습니다. 발표에는 '1상 b 단계 단일군 오픈 라벨 연구: 개선된 ADCC를 가진 항-CD19 단클론 항체인 부도프루투그가 있는 원발막성 신병증'이라는 제목의 포스터가 포함됩니다.
발표자는 뉴욕 신장 혈관염 및 사구체 신병센터의 책임자인 프랭크 코르타자르 박사입니다. 그는 세인트피터 병원 신장학 부서의 책임자이며, 세인트피터 헬스 파트너스의 임상 연구 책임자이자 매사추세츠 종합병원의 임상 과학자입니다. 포스터 세션은 원발막성 신병증, FSGS 및 최소 변화 질환에 중점을 두고 있으며, 2024년 10월 24일 오전 10시부터 오후 12시(태평양 표준시)까지 예정되어 있으며 포스터 번호는 TH-PO587입니다.
Climb Bio (Nasdaq: CLYM) a annoncé qu'elle présentera des données lors de la Semaine des reins 2024 de la Société américaine de néphrologie, qui se tiendra à San Diego, Californie, du 23 au 27 octobre 2024. La présentation comprendra un poster intitulé 'Une étude ouverte de phase 1b avec un bras unique de Budoprutug, un anticorps monoclonal anti-CD19 avec un ADCC amélioré, dans la néphropathie membranale primaire'.
Le présentateur sera le Dr. Frank Cortazar, Directeur du New York Nephrology Vasculitis and Glomerular Center, Chef de la Division de Néphrologie à l'Hôpital St. Peter, Chef de la Recherche Clinique chez St. Peter's Health Partners, et Scientifique Clinique à l'Hôpital Général du Massachusetts. La session d'affichage, axée sur la néphropathie membranale, le FSGS et la maladie à changement minime, est prévue pour le 24 octobre 2024, de 10h00 à 12h00 PT, avec le numéro d'affiche TH-PO587.
Climb Bio (Nasdaq: CLYM) hat angekündigt, dass es Daten auf der American Society of Nephrology Kidney Week 2024 präsentieren wird, die vom 23. bis 27. Oktober 2024 in San Diego, Kalifornien, stattfindet. Die Präsentation wird ein Poster mit dem Titel 'Eine Phase 1b Einarmige Open-Label-Studie von Budoprutug, einem anti-CD19 monoklonalen Antikörper mit verbessertem ADCC, bei primärer membranöser Nephropathie' umfassen.
Der Präsentator wird Dr. Frank Cortazar sein, Direktor des New York Nephrology Vasculitis and Glomerular Center, Leiter der Abteilung für Nephrologie am St. Peter's Hospital, Leiter der klinischen Forschung bei St. Peter's Health Partners und klinischer Wissenschaftler am Massachusetts General Hospital. Die Postersitzung, die sich auf die membranöse Nephropathie, FSGS und die Erkrankung mit minimalen Veränderungen konzentriert, ist für den 24. Oktober 2024, von 10:00 bis 12:00 Uhr PT, mit der Poster-Nummer TH-PO587 geplant.
- Climb Bio's research on Budoprutug, an anti-CD19 monoclonal antibody, selected for presentation at a major nephrology conference
- Study focuses on Primary Membranous Nephropathy, potentially expanding Climb Bio's therapeutic reach in kidney diseases
- None.
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024.
Poster Presentation
A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous Nephropathy
Presenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;
Chief, Division of Nephrology, St. Peter's Hospital; Chief, Clinical Research, St. Peter's Health Partners;
Clinical Scientist, Massachusetts General Hospital
Session Title: Membranous Nephropathy, FSGS, and Minimal Change Disease [PO1402-1]
Session Date, Time: October 24, 2024 from 10:00 a.m. to 12:00 p.m. PT
Poster Board #: TH-PO587
About Climb Bio, Inc.
Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com.
Investors
Chris Brinzey
ICR Westwicke
339-970-2843
Media
Jon Yu
ICR Westwicke
jon.yu@westwicke.com
475-395-5375
FAQ
What is Climb Bio presenting at the American Society of Nephrology Kidney Week 2024?
When and where is the American Society of Nephrology Kidney Week 2024 taking place?
Who is presenting Climb Bio's (CLYM) research at the Kidney Week 2024?
What is the specific date and time for Climb Bio's (CLYM) poster presentation at Kidney Week 2024?
